Immunophotonics Announces First Patient Dosed in Phase 2a Clinical Trial of IP-001 in advanced solid tumor indications
ST. LOUIS, MISSOURI AND BERN, SWITZERLAND, May 10, 2022 /EINPresswire.com/ — Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs in oncology and infectious disease, has announced that the first patient has been dosed in the phase 2a portion of its clinical trial for treatment of a variety…